MedTrace Logo

Study to Assess PDM608 in Healthy Adult Subjects

NCT05950906 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 64

Last updated 2025-11-18

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to assess the safety, tolerability and pharmacokinetics of PDM608 in healthy adult subjects.

Conditions

  • Parkinson Disease

Interventions

DRUG

PDM608

PDM608 subcutaneous at single or multiple dose(s) assigned by cohort

DRUG

Placebo

Placebo subcutaneous at single or multiple dose(s) to match PDM608 administration.

Sponsors & Collaborators

  • Michael J. Fox Foundation for Parkinson's Research

    collaborator OTHER

  • Alzheimer's Drug Discovery Foundation

    collaborator OTHER

  • Calibr, a division of Scripps Research

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-06-27
Primary Completion
2024-03-17
Completion
2024-04-19
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05950906 on ClinicalTrials.gov